(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Lupus Nephritis pipeline constitutes 20+ key companies continuously working towards developing 25+ Lupus Nephritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Lupus Nephritis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lupus Nephritis Market.
The Lupus Nephritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Lupus Nephritis Pipeline Report:
- Companies across the globe are diligently working toward developing novel Lupus Nephritis treatment therapies with a considerable amount of success over the years.
- Lupus Nephritis companies working in the treatment market are Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others, are developing therapies for the Lupus Nephritis treatment
- Emerging Lupus Nephritis therapies in the different phases of clinical trials are- IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others are expected to have a significant impact on the Lupus Nephritis market in the coming years.
- In July 2023, Kyverna Therapeutics (“Kyverna”), a cell therapy company with the goal of creating a new class of treatments for severe autoimmune diseases, announced today that the Paul-Ehrlich-Institut (PEI) in Germany has approved its first Clinical Trial Application (CTA) for KYV101, a cutting-edge therapy for the treatment of lupus nephritis (LN). In order to treat autoimmune disorders caused by B cells, such as LN, KYV-101 is a unique, totally human anti-CD19 CAR T-cell therapy. It provides a ground-breaking strategy for battling autoimmune diseases by utilising the body’s immune system
Lupus Nephritis Overview
One of the most serious organ symptoms of systemic lupus erythematosus (SLE), an autoimmune disease that results in the loss of immunological tolerance to endogenous nuclear material and systemic autoimmunity, is lupus nephritis (LN).
Get a Free Sample PDF Report to know more about Lupus Nephritis Pipeline Therapeutic Assessment - https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight
Emerging Lupus Nephritis Drugs Under Different Phases of Clinical Development Include:
- IBL-101: Inflection Biosciences
- RG 6107: Roche
- Itolizumab: Equillium
- Zanubrutinib: BeiGene
- Guselkumab: Janssen Research & Development
- Daxdilimab: Horizon Therapeutics
- Secukinumab: Novartis
- Obinutuzumab: Roche
- GAZYVA: Roche
- Saphnelo (Anifrolumab): AstraZeneca
- Iscalimab: Novartis
- Cosentyx: Novartis
- Ravulizumab: Alexion Pharmaceuticals
- Anifrolumab: AstraZeneca
Lupus Nephritis Route of Administration
Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Lupus Nephritis Molecule Type
Lupus Nephritis Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Lupus Nephritis Pipeline Therapeutics Assessment
- Lupus Nephritis Assessment by Product Type
- Lupus Nephritis By Stage and Product Type
- Lupus Nephritis Assessment by Route of Administration
- Lupus Nephritis By Stage and Route of Administration
- Lupus Nephritis Assessment by Molecule Type
- Lupus Nephritis by Stage and Molecule Type
DelveInsight’s Lupus Nephritis Report covers around 25+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Lupus Nephritis product details are provided in the report. Download the Lupus Nephritis pipeline report to learn more about the emerging Lupus Nephritis therapies
Some of the key companies in the Lupus Nephritis Therapeutics Market include:
Key companies developing therapies for Lupus Nephritis are – Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, Novartis Pharmaceuticals, Hoffmann-La Roche, Janssen Research & Development, BeiGene, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Alexion Pharmaceuticals, Omeros Corporation, Corestem, Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Apellis Pharmaceuticals, AstraZeneca, Kezar Life Sciences, Equillium, Eledon Pharmaceuticals, Resolve Therapeutics, and others.
Lupus Nephritis Pipeline Analysis:
The Lupus Nephritis pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Lupus Nephritis with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis Treatment.
- Lupus Nephritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Lupus Nephritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lupus Nephritis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Lupus Nephritis drugs and therapies
Lupus Nephritis Pipeline Market Drivers
- Increasing Prevalence of Lupus Nephritis, increase in research and developmental activities are some of the important factors that are fueling the Lupus Nephritis Market.
Lupus Nephritis Pipeline Market Barriers
- However, high-cost associated with the disease, lack of awareness among the patients about the disease and other factors are creating obstacles in the Lupus Nephritis Market growth.
Scope of Lupus Nephritis Pipeline Drug Insight
- Coverage: Global
- Key Lupus Nephritis Companies: Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others, and others
- Key Lupus Nephritis Therapies: IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others
- Lupus Nephritis Therapeutic Assessment: Lupus Nephritis current marketed and Lupus Nephritis emerging therapies
- Lupus Nephritis Market Dynamics: Lupus Nephritis market drivers and Lupus Nephritis market barriers
Request for Sample PDF Report for Lupus Nephritis Pipeline Assessment and clinical trials
Table of Contents
- Lupus Nephritis Report Introduction
- Lupus Nephritis Executive Summary
- Lupus Nephritis Overview
- Lupus Nephritis- Analytical Perspective In-depth Commercial Assessment
- Lupus Nephritis Pipeline Therapeutics
- Lupus Nephritis Late Stage Products (Phase II/III)
- Lupus Nephritis Mid Stage Products (Phase II)
- Lupus Nephritis Early Stage Products (Phase I)
- Lupus Nephritis Preclinical Stage Products
- Lupus Nephritis Therapeutics Assessment
- Lupus Nephritis Inactive Products
- Company-University Collaborations (Licensing/Partnering) Analysis
- Lupus Nephritis Key Companies
- Lupus Nephritis Key Products
- Lupus Nephritis Unmet Needs
- 16 . Lupus Nephritis Market Drivers and Barriers
- Lupus Nephritis Future Perspectives and Conclusion
- Lupus Nephritis Analyst Views
- Appendix
- About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
